903550-26-5

Basic information

• Product Name: 1-(Tetrahydropyran-2-yl)-1H-pyrazole-5-boronic acid pinacol ester
• Synonyms: 1-(Tetrahydropyran-2-yl)-1H-pyrazole-5-boronic acid pinacol ester;1-(2-Tetrahydropyranyl)-1H-pyrazole-5-boronic acid pinacol ester, 95%;1-(Tetrahydro-2H-pyran-2-yl)-1H-pyrazole-5-boronic acid pinacol ester;1-(Tetrahydro-2H-pyran-2-yl)-1H-indazole-5-boronic acid pinacol ester;1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1-(Tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-y)-1H-pyrazole;1-(oxan-2-yl)-5-(tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1H-Pyrazole,1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
• CAS NO: 903550-26-5
• Molecular Formula: C₁₄H₂₃BN₂O₃
• Molecular Weight: 278.16
• Mol File: 903550-26-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 74-78℃
• Boiling Point: 413.793 °C at 760 mmHg
• Flash Point: 204.055 °C
• Appearance: /
• Density: 1.16 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.545
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Sparingly), DMSO (Sparingly, Sonicated), Methanol (Slightly, Sonicat
• PKA: 2.06±0.19(Predicted)
• CAS DataBase Reference: 1-(Tetrahydropyran-2-yl)-1H-pyrazole-5-boronic acid pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(Tetrahydropyran-2-yl)-1H-pyrazole-5-boronic acid pinacol ester(903550-26-5)
• EPA Substance Registry System: 1-(Tetrahydropyran-2-yl)-1H-pyrazole-5-boronic acid pinacol ester(903550-26-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 24/25
• WGK Germany: 3
• TSCA: No
• Hazardous Substances Data: 903550-26-5(Hazardous Substances Data)

Usage

Uses

[1-(Tetrahydropyran-2-yl)-1H-pyrazol-5-yl]boronic Acid Pinacol Ester can be used for a pharmaceutical drug to treat constipation due to having an excellent sodium ion/hydrogen ion exchanger 3 inhibitory action.

InChI:InChI=1/C14H23BN2O3/c1-13(2)14(3,4)20-15(19-13)11-8-9-16-17(11)12-7-5-6-10-18-12/h8-9,12H,5-7,10H2,1-4H3

Upstream product

• 76-09-5 2,3-dimethyl-2,3-butane diol 
• 449758-17-2 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole 
• 61676-62-8 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 5419-55-6 Triisopropyl borate 
• 1217902-60-7 Diisopropyl 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-ylboronate 
• 110-87-2 3,4-dihydro-2H-pyran 

Downstream Products

• 903550-30-1 5-(2-bromo-phenyl)-1-(tetrahydro-pyran-2-yl)-1H-pyrazole 
• 903550-33-4 5-(3-methoxy-phenyl)-1-(tetrahydro-pyran-2-yl)-1H-pyrazole 
• 903550-34-5 2-[2-(tetrahydro-pyran-2-yl)-2H-pyrazol-3-yl]-benzonitrile 
• 903550-29-8 2-[2-(tetrahydro-pyran-2-yl)-2H-pyrazol-3-yl]-benzoic acid methyl ester 
• 903550-27-6 1-(tetrahydro-pyran-2-yl)-5-p-tolyl-1H-pyrazole 
• 903550-31-2 5-(2-chloro-phenyl)-1-(tetrahydro-pyran-2-yl)-1H-pyrazole 
• 903550-28-7 2-[2-(tetrahydro-pyran-2-yl)-2H-pyrazol-3-yl]-benzoic acid ethyl ester 
• 943615-59-6 C₁₅H₁₅FN₂O₃ 
• 943615-32-5 C₁₇H₂₀N₂O₄ 
• 943615-48-3 C₁₅H₁₆N₂O₃ 
• 943615-49-4 C₁₆H₁₈N₂O₄ 
• 1028092-51-4 4-[2-(tetrahydropyran-2-yl)-2H-pyrazol-3-yl]benzonitrile 
• 1028092-47-8 5-phenyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole 
• 1028092-46-7 5-(4-fluorophenyl)-1-(tetrahydropyran-2-yl)-1H-pyrazole 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF

The present invention relates to an improved process for the preparation of carboxamide structured androgen receptor (AR) antagonists such as N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H- pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3- carboxamide (1A) and key intermediates thereof such as 2-chloro-4- (IH-pyrazol-3-yl)benzonitrile (V). AR antagonists are useful in the treatment of cancer, particularly prostate cancer and other diseases where AR antagonism is desired.

3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS

3,4-diarylpyrazole derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

A simple, modular method for the synthesis of 3,4,5-trisubstituted pyrazoles

(Chemical Equation Presented) A modular approach for the regiocontrolled preparation of pyrazoles bearing substituents on all three carbon atoms is described. Central to this method is the use of a switchable metal-directing group (MDG) to enable sequential direct lithiation of the 3- and 5-positions of the pyrazole ring. Pyrazole boronic esters obtained from these lithiated intermediates can undergo efficient Suzuki cross-coupling under the developed nonaqueous conditions, which minimize undesirable protolytic deboronation. Halogenation of the 4-position provides the means for substitution at the remaining carbon atom.